SCHEDULE 13G
SCHEDULE 13GSchedule 13G ownership disclosure
Palvella Therapeutics Inc
Common Stock · CUSIP: 697947109
Event date: 2024-12-13
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Frazier Life Sciences Public Fund, L.P.
Shares: 440,575.00 · Class: 3.9%
- FHMLSP, L.P.
Shares: 440,575.00 · Class: 3.9%
- FHMLSP, L.L.C.
Shares: 440,575.00 · Class: 3.9%
- Frazier Life Sciences Public Overage Fund, L.P.
Shares: 129,905.00 · Class: 1.2%
- FHMLSP Overage, L.P.
Shares: 129,905.00 · Class: 1.2%
- FHMLSP Overage, L.L.C.
Shares: 129,905.00 · Class: 1.2%
- Frazier Life Sciences X, L.P.
Shares: 2,648.00 · Class: 0.0%
- FHMLS X, L.P.
Shares: 2,648.00 · Class: 0.0%
- FHMLS X, L.L.C.
Shares: 2,648.00 · Class: 0.0%
- Frazier Life Sciences XI, L.P.
Shares: 2,764.00 · Class: 0.0%
- FHMLS XI, L.P.
Shares: 2,764.00 · Class: 0.0%
- FHMLS XI, L.L.C.
Shares: 2,764.00 · Class: 0.0%
- James N. Topper
Shares: 575,892.00 · Class: 5.1%
- Patrick J. Heron
Shares: 575,892.00 · Class: 5.1%
- Albert Cha
Shares: 570,480.00 · Class: 5.1%
- James Brush
Shares: 570,480.00 · Class: 5.1%
- Daniel Estes
Shares: 2,764.00 · Class: 0.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-001108
- Form type
- SCHEDULE 13G
- Filer
- Frazier Life Sciences Public Fund, L.P.
- CIK
- CIK 1863769
- Filed
- Jan 08, 2025
- Reporting period
- Dec 13, 2024
- Description
- Schedule 13G beneficial ownership